Treatment of knee joint osteoarthritis in overweight women in outpatient practice

Objectives: evaluation of the clinical efficacy and safety of the healthy joints maintaining compound Artroflex^® in knee osteoarthritis (OA) in postmenopausal overweight women in outpatient clinical practice.
Patients and methods. An open, prospective observational single-center post-marketing study included 30 postmenopausal women 50–75 years old (mean age 62.3±6.3 years) with knee OA. Patient body mass index (BMI) was >25 (mean body weight 85.3±15.3 kg). Radiographically confirmed primary gonarthrosis stage II according to Kellgren–Lawrence was detected in 26 (87.0%) patients, stage III – in 4 (13.0%). The duration of knee OA ranged from 1 to 21 years (average 7.8±6.1 years).
Artroflex^® was prescribed 1 capsule 2 times a day for 3 months. During three visits (baseline, after 1 and 3 months), the need for analgesics or non-steroidal anti-inflammatory drugs (NSAIDs) and the occurrence of adverse reactions (AR) were determined. Health status and pain level were also assessed using a visual analogue scale (VAS), the severity of pain and stiffness, limited function according to the WOMAC questionnaire, fatigue/fatigue according to the FACIT scale, the Charlson comorbidity index, satisfaction of the doctor with the results of treatment using the IMOS scale, and satisfaction of the patient with using the IMPSS scale.
Results and discussion. A statistically significant decrease in the pain score according to the VAS, an improvement in health status, and the WOMAC index were found in the overwhelming number of patients, regardless of BMI. 90% of women noted decrease in fatigue/fatigue on the FACIT scale, and 93% of patients reported satisfaction with treatment, regardless of the Charlson comorbidity index. The need for NSAIDs after one month of use of the Artroflex^® compound decreased by 7%, after 3 months – by 23%. A negative feedback was found between the baseline indicator of health status and the assessment of the effectiveness of therapy. No serious ARs were identified during the study.
Conclusion. Feasibility of using the Artroflex^® compound in real clinical practice in patients with knee OA and excessive body mass has been shown.

1. Alekseeva LI, Taskina EA, Kashevarova NG. Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2019;13(2):9-21. (In Russ.). doi: 10.14412/1996-7012-2019-2-9-21.

2. Alekseeva LI, Sharapova EP, Kashevarova NG, P'yanykh SE. New opportunities in the treatment of osteoarthritis. Spravochnik poliklinicheskogo vracha. 2015;(6-8):4-7. (In Russ.).

3. Lapshina SA, Feiskhanova LI, Nurmieva AR, Sadriev KA. Osteoarthritis in patients with components of the metabolic syndrome. Terapiya. 2019;5(8):52-8. (In Russ.).

4. http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography/

5. Lila AM, Alekseeva LI, Taskina EA. Modern approaches to the treatment of osteoarthritis, taking into account updated international recommendations. Russkii meditsinskii zhurnal. Meditsinskoe obozrenie. 2019;3(11-2): 48-52. (In Russ.).

6. Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of kneeosteoarthritis from the EuropeanSociety for Clinical and EconomicAspects of Osteoporosis, Osteoarthritis and MusculoskeletalDiseases (ESCEO). Semin Arthritis Rheum. 2019 Apr 30, pii: S0049-0172(19)30043-5. doi: 10.1016/j.semarthrit.2019.04.008.

7. Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2017. 464 p.

8. Rovati LC, Girolami F, Persiani S. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther Adv Musculoskelet Dis. 2012 Jun;4(3):167-80. doi: 10.1177/1759720X12437753.

9. Bruyere O, Cooper C, Al-Daghri NM, et al. Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res. 2018 Feb;30(2):111-7. doi: 10.1007/s40520-017-0861-1. Epub 2017 Nov 24.

10. Hoffer LJ, Kaplan LN, Hamadeh MJ, et al. Sulfate could mediate the therapeutic effect of glucosamine sulfate. Metabolism. 2001 Jul;50(7):767-70. doi: 10.1053/meta.2001.24201.

11. Cordoba F, Nimni ME. Chondroitin sulfate and other sulfate containing chondroprotective agents may exhibit their effects by overcoming a deficiency of sulfur amino acids. Osteoarthritis Cartilage. 2003 Mar;11(3):228-30. doi: 10.1016/s1063-4584(02)00351-5.

12. Zhang K, Liu Y, Zhao X, et al. Antiinflammatory properties of GLPss58, a sulfated polysaccharide from Ganoderma lucidum. Int J Biol Macromol. 2018 Feb;107(Pt A):486-493. doi: 10.1016/j.ijbiomac.2017.09.015

13. Karateev AE, Barysheva YuV, Belokon YaV, et al. Evaluation of the efficacy and safety of a combination of chondroitin sulfate and glucosamine sulfate for knee and hip osteoarthritis in real clinical practice. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2020;14(4):82-90. (In Russ.). doi: 10.14412/1996-7012-2020-4-82-90